Sensorion strengthens its management team with the appointment of David Lawrence as Chief Financial Officer
Montpellier, February 27, 2023 – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company dedicated to the development of innovative therapies to restore, treat and prevent hearing loss, announces the appointment of David Lawrence as Chief Financial Officer, from March 1, 2023.
Mr. Lawrence was previously the Chief Financial Officer of Valneva